Glenmark Pharma surges on getting approval for Raloxifene Hydrochloride Tablets

23 Mar 2016 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 832.00, up by 10.75 points or 1.31% from its previous closing of Rs. 821.25 on the BSE.

The scrip opened at Rs. 822.10 and has touched a high and low of Rs. 833.80 and Rs. 822.10 respectively. So far 6879 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 671.50 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 836.00 and Rs. 778.35 respectively. The current market cap of the company is Rs. 23172.24 crore.

The promoters holding in the company stood at 46.47% while Institutions and Non-Institutions held 42.50% and 11.02% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Raloxifene Hydrochloride Tablets USP, 60 mg, the therapeutic equivalent to the reference listed drug product, Evista Tablets, 60 mg, of Eli Lilly and Company.

According to IMS Health sales data for the 12 month period ending January 2016, the Evista Market achieved annual sales of approximately $336.5 million.

Glenmark's current portfolio consists of 109 products authorized for distribution in the U.S. marketplace and 60 ANDA's pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

2023.85 -12.05 (-0.59%)
01-Jan-2026 10:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.05
Dr. Reddys Lab 1251.30
Cipla 1503.05
Zydus Lifesciences 909.40
Lupin 2083.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×